The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis

Shiwei Liu(University of Electronic Science and Technology of China), Hao Wang(University of Electronic Science and Technology of China), Xin Yu(Anhui Institute of Architectural Research and Design), Miao Yu(University of Electronic Science and Technology of China), Meihua Wang(University of Electronic Science and Technology of China), Hao Tang(Roche (China)), Exian Mou(University of Electronic Science and Technology of China), Kun Mi(Sichuan Cancer Hospital), Hui Li(University of Electronic Science and Technology of China), Yajing Feng(Zhengzhou University), Shuanghua Liu(University of Electronic Science and Technology of China)
Scientific Reports
January 3, 2025
10.1038/s41598-024-84039-2
Cited by 4

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
|Cancer Discovery|2014|1.5k
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|477
Influenza vaccination rate and its association with chronic diseases in China: Results of a national cross-sectional study
|Vaccine|2020|96